Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 50

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 50
---
 and development expenses amounted to $87,661 constituting the second largest expense recognized during that quarter.

Other Income

For the three months ended March 31 2025, the Company reported a net other income of $93,995 whereas in the same period ended 2024 the Company reported the net other expense of $(21,383). Net other income was primarily driven by the recognition of a Derivative Gain of $128,963 in 2025. For the quarter ended March 31, 2025 the Company also recognized higher interest and amortization expenses as compared to the quarter ended 2024. .

For the six months ended March 31 2025, the Company reported a net other expense of $(360,012) whereas in the same period ended 2024 the Company reported the net other expense of $(43,534) Net other income was primarily driven by the recognition of a Derivative Expense in of $(287,053) in 2025. For the period ended March 31, 2025 the Company also recognized higher interest and amortization expenses as compared to the quarter ended 2024.

Net Loss

The Company recognized an Operating Loss of $ 113,349 during the three months ended March 31, 2025 whereas the Company recognized an Operating Loss of $ 101,071 for the same period ended 2024. The reduction in operating loss is primarily attributable to a reduction in all expense categories other than rent incurred during the period ended 2024 as compared to the quarter ended in 2025.

The Company recognized an Operating Loss of $ 174,727 during the six months ended March 31, 2025 whereas the Company recognized an Operating Loss of $ 223,853 for the same period ended 2024. The reduction in operating loss is primarily attributable to a reduction in all expense categories other than rent incurred during the period ended 2025 as compared to the quarter ended in 2025.

Net Loss is $ 19,354 for the three months ended March 31, 2025 as opposed to a Net Loss of $122,454 for the same period ended 2024. The difference is primarily attributable to the recognition by the Company of a Derivative Gain of $128,963 in 2025.

Net Loss is $ 534,739 For the six months ended March 31, 2025 as opposed to a Net Loss of $267,387 for the same period ended 2024. The difference is primarily attributable to the recognition